Enfuvirtide

DB00109

biotech approved investigational

Deskripsi

Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 3.8 +/- 0.6 hrs
Volume Distribusi * 5.5 ± 1.1 L
Klirens (Clearance) * 24.8 +/- 4.1 mL/h/kg [HIV-1 infected adult and pediatric subjects following a 90-mg single SC dose of enfuvirtide] * 30.6 +/- 10.6 mL/h/kg [Following 90-mg twice daily dosing of FUZEON SC in combination with other antiretroviral agents in HIV-1 infected subjects] * 40 +/- 17 mL/h/kg [pediatric patients in the presence of concomitant medications including antiretroviral agents receiving the 2 mg/kg twice daily dose]

Absorpsi

After a 90 mg single subcutaneous injection of Enfuvirtide into the abdomen in 12 HIV-1 infected subjects, the mean peak concentration is 4.59+/-1.5 ug/ml and the median time to peak concentration was 8 hours (ranged from 3 to12 hours).

Metabolisme

Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

15 Data
Ritonavir The serum concentration of Enfuvirtide can be increased when it is combined with Ritonavir.
Rubella virus vaccine The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Enfuvirtide.
Bacillus calmette-guerin substrain tice live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Enfuvirtide.
Bacillus calmette-guerin substrain connaught live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Enfuvirtide.
Yellow fever vaccine The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Enfuvirtide.
Anthrax vaccine The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Enfuvirtide.
Typhoid Vaccine Live The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Enfuvirtide.
BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Enfuvirtide.
Human adenovirus e serotype 4 strain cl-68578 antigen The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Enfuvirtide.
Vibrio cholerae CVD 103-HgR strain live antigen The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Enfuvirtide.
Adenovirus type 7 vaccine live The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Enfuvirtide.
Varicella zoster vaccine (live/attenuated) The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Enfuvirtide.
Bacillus calmette-guerin substrain russian BCG-I live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Enfuvirtide.
Chikungunya vaccine (live, attenuated) The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Enfuvirtide.
Smallpox (Vaccinia) Vaccine, Live The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Enfuvirtide.

Target Protein

Envelope glycoprotein gp41

Referensi & Sumber

Synthesis reference: Ananda Kuppanna, Reddy Maria Bhaskar Reddy Komma, Debashish Datta. An improved process for the preparation of enfuvirtide. WO2011095989A2 (Issued Aug 11, 2011).
Artikel (PubMed)
  • PMID: 15231762
    Greenberg ML, Cammack N: Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother. 2004 Aug;54(2):333-40. Epub 2004 Jul 1.

Contoh Produk & Brand

Produk: 4 • International brands: 0
Produk
  • Fuzeon
    Kit • - • Subcutaneous • US • Approved
  • Fuzeon
    Injection, powder, lyophilized, for solution; Kit • 90 mg/1mL • Subcutaneous • US • Approved
  • Fuzeon
    Powder, for solution • 108 mg / vial • Subcutaneous • Canada • Approved
  • Fuzeon
    Injection, powder, for solution • 90 mg/ml • Subcutaneous • EU • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul